Background Despite a clear mortality benefit, 1 US Preventive Services Task Force (USPSTF) endorsement, and Centers for Medicare & Medicaid coverage, uptake of lung cancer screening with annual low-dose CT (LDCT) remains remarkably limited. As
Search Results
Geographic Accessibility and Completion of Initial Low-Dose CT-Based Lung Cancer Screening in an Urban Safety-Net Population
Sofia Yi, Rutu A. Rathod, Vijaya Subbu Natchimuthu, Sheena Bhalla, Jessica L. Lee, Travis Browning, Joyce O. Adesina, Minh Do, David Balis, Juana Gamarra de Wiliams, Ellen Kitchell, Noel O. Santini, David H. Johnson, Heidi A. Hamann, Simon J. Craddock Lee, Amy E. Hughes, and David E. Gerber
Cervical Cancer Screening
Edward E. Partridge, Nadeem Abu-Rustum, Anna Giuliano, Stewart Massad, Joan McClure, Mary Dwyer, and Miranda Hughes
recent changes to cervical cancer screening recommendations and management of abnormal screening test results Describe the rationale behind the recent changes in management for cervical cancer screening Overview Cervical cytology screening
Disparities in Electronic Screening for Cancer-Related Psychosocial Distress May Promote Systemic Barriers to Quality Oncologic Care
Thomas L. Sutton, Marina Affi Koprowski, Jeffrey A. Gold, Benjamin Liu, Alison Grossblatt-Wait, Caroline Macuiba, Andrea Lehman, Susan Hedlund, Flavio G. Rocha, Jonathan R. Brody, and Brett C. Sheppard
Background Screening for psychosocial distress in patients with cancer has become a well-established component of integrative oncologic care, as timely identification of distress and appropriate referrals have been shown to improve well
NCCN Guidelines as a Model of Extended Criteria for Lung Cancer Screening
Brady J. McKee, Shawn Regis, Andrea K. Borondy-Kitts, Jeffrey A. Hashim, Robert J. French Jr, Christoph Wald, and Andrea B. McKee
Background NCCN, the Centers for Medicare & Medicaid Services (CMS), and the US Preventive Services Task Force (USPSTF) recommend annual CT lung screening (CTLS) for current and former heavy smokers meeting the National Lung Screening Trial
Factors Associated With False-Positive Recalls in Mammography Screening
Xinhe Mao, Wei He, Keith Humphreys, Mikael Eriksson, Natalie Holowko, Fredrik Strand, Per Hall, and Kamila Czene
Background Mammography screening reduces breast cancer mortality by an estimated 26% to 41%. 1 , 2 However, false-positive recalls—recalling women with abnormal mammograms who, on further testing, are not found to have breast cancer—can cause
Lung Cancer Screening With Low-Dose Computed Tomography: Costs, National Expenditures, and Cost-Effectiveness
Bernardo H. L. Goulart, Mark E. Bensink, David G. Mummy, and Scott D. Ramsey
disease is rarely curable. Lung cancer screening tests can potentially reduce cancer mortality through detecting tumors at earlier stages, when treatments have higher chances of cure. 2 , 3 The NCI-sponsored National Lung Screening Trial (NLST) is the
Current Status of Distress Screening in Designated Cancer Hospitals: A Cross-Sectional Nationwide Survey in Japan
Toru Okuyama, Yoshiyuki Kizawa, Tatsuya Morita, Hiroya Kinoshita, Megumi Uchida, Asami Shimada, Akemi Shirado Naito, and Tatsuo Akechi
distress screening, 8 , 11 but recent evidence indicates that patients with cancer may not obtain a substantial benefit from screening itself. 12 – 14 Screening is considered just one step in a comprehensive screening program that consists of detailed
NCCN Guidelines® Insights: Colorectal Cancer Screening, Version 1.2024
Featured Updates to the NCCN Guidelines
Reid M. Ness, Xavier Llor, Mohammad Ali Abbass, Shrinivas Bishu, Christopher T. Chen, Gregory Cooper, Dayna S. Early, Mark Friedman, David Fudman, Francis M. Giardiello, Kathryn Glaser, Surya Gurudu, Michael Hall, Lyen C. Huang, Rachel Issaka, Bryson Katona, Trilokesh Kidambi, Audrey J. Lazenby, Jennifer Maratt, Arnold J. Markowitz, Joseph Marsano, Folasade P. May, Robert J. Mayer, Kinga Olortegui, Swati Patel, Shajan Peter, Laura D. Porter, Mehnaz Shafi, Peter P. Stanich, Jonathan Terdiman, Peter Vu, Jennifer M. Weiss, Elizabeth Wood, Carly J. Cassara, and Vaishnavi Sambandam
: September 10, 2024; Expiration date: September 10, 2025 Learning Objectives: Upon completion of this activity, participants will be able to: • Integrate into professional practice the updates to the NCCN Guidelines for Colorectal Cancer Screening
Colorectal Cancer Screening
Randall W. Burt, James S. Barthel, Kelli Bullard Dunn, Donald S. David, Ernesto Drelichman, James M. Ford, Francis M. Giardiello, Stephen B. Gruber, Amy L. Halverson, Stanley R. Hamilton, Mohammad K. Ismail, Kory Jasperson, Audrey J. Lazenby, Patrick M. Lynch, Edward W. Martin Jr., Robert J. Mayer, Reid M. Ness, Dawn Provenzale, M. Sambasiva Rao, Moshe Shike, Gideon Steinbach, Jonathan P. Terdiman, and David Weinberg
Colorectal Cancer Screening Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN
Lung Cancer Screening, Version 1.2015
Douglas E. Wood, Ella Kazerooni, Scott L. Baum, Mark T. Dransfield, George A. Eapen, David S. Ettinger, Lifang Hou, David M. Jackman, Donald Klippenstein, Rohit Kumar, Rudy P. Lackner, Lorriana E. Leard, Ann N.C. Leung, Samir S. Makani, Pierre P. Massion, Bryan F. Meyers, Gregory A. Otterson, Kimberly Peairs, Sudhakar Pipavath, Christie Pratt-Pozo, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter, Peter B. Sachs, Matthew B. Schabath, Lecia V. Sequist, Betty C. Tong, William D. Travis, Stephen C. Yang, Kristina M. Gregory, and Miranda Hughes
, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Lung Cancer Screening Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Lung Cancer Screening
